What is Saccharomyces boulardii CNCM I-745?

Saccharomyces boulardii CNCM I-745 is a single-strain yeast probiotic. This specific yeast strain addresses the causes and symptoms of diarrhea as well as helps maintain the balance of beneficial microbiota.¹

The multiple benefits of S. boulardii CNCM I-745 have been extensively demonstrated thanks to its long history as a probiotic.¹

It was discovered by the French microbiologist Henri Boulard in 1923¹, who while in South East Asia, observed that people drinking a special tea made from the skins of mangosteens and litchis did not develop diarrhea.²

Since it was first discovered, the benefits of S. boulardii CNCM I-745 have been investigated in more than 100 clinical trials , and it has been available as a probiotic treatment for diarrhea for over 56 years.² In fact, S. boulardii CNCM I-745 was the first yeast probiotic drug used in human medicine³.

S. boulardii CNCM I-745 is a non-pathogenic single-strain yeast probiotic that differs from other bacterial and yeast probiotics

due to its strain-specific properties, its proven specific mechanisms of action (MOA), as well as a unique manufacturing process and proven benefits backed by high quality scientific and clinical evidence.^1,4

(Internal code : 20.15)

S. boulardii CNCM I-745 has many strain-specific qualities:

It has a high tolerance to acid, meaning that it can pass through the stomach into the lower gastrointestinal tract without being destroyed.⁴
Unlike other yeast members of the Saccharomyces family the ideal temperature for its growth is at the same temperature as the human body.⁴
It is also naturally resistant to antibiotics⁵, meaning that it can be administered at the same time as antibiotics.
It does not permanently colonise the gut so does not upset the normal balance of microbiota.^1,4

Saccharomyces boulardii CNCM I-745 addresses the causes of diarrhea through multiple specific and proven mechanisms of action.⁴ It acts directly to counteract harmful microbes and their activity, enhances the gut’s immune response to these microbes, reduces inflammatory responses, and encourages a return to a healthy gut environment by restoring the balance of normal microbiota, as well as influencing normal gut processes that keep the gut working properly.^1,4

In this way, S. boulardii CNCM I-745 is a solution for a complete approach to diarrhea, by addressing intestinal dysbiosis.

S. boulardii CNCM I-745 prevents and treats diarrhea as well as can restore intestinal microbiota following gut imbalance.⁶

This yeast, which is registered as a drug in many countries due to its quality of scientific and clinical evidence, can:

prevent antibiotic-associated diarrhea when taken during antibiotic treatment⁶;
prevent recurrent Clostridium difficile disease⁶;
treat acute (infectious) diarrhea⁴ ;
reduce Helicobacter pylori eradication therapy-associated side effects⁶;
aid in the recovery of normal gut microbiota following an imbalance in composition and diversity¹.

Internal code : 20.55

References

01 . More MI, and Swidsinski, A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis–a review. Clinical and experimental gastroenterology. 2015; 8: 237.
02 . Data on file_Biocodex_2019
03 . Joly, F et al. 2017. Saccharomyces boulardii CNCM I-745. Marteau, P and Dore J (Ed.), Gut Microbiota: A full-fledged organ. 2017: 305-326. Paris: John Libbey Eurotext.

See more See less

04 . McFarland, LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG. 2010; 16(18): 2202.
05 . Neut C, Mahieux S, and Dubreuil LJ. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Medecine et maladies infectieuses. 2017; 47(7): 477-483.
06 . Czerucka D, and Rampal, P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World journal of gastroenterology. 2019; 25(18): 2188.